Exposome Epidemiology for Suspect Environmental Chemical Exposures during Pregnancy Linked to Subsequent Breast Cancer Diagnosis

Young-Mi Go¹, Jaclyn Weinberg¹, Sami Teeny¹, Piera Cirillo², Nickilou Krigbaum², Grant Singer¹, ViLinh Ly¹, Barbara Cohn^{2†} and Dean P. Jones^{1†}

¹ Clinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA 30322

² The Center for Research on Women and Children's Health, Child Health and Development Studies, Public Health Institute, Berkeley, CA 94709

Running Head: Exposome epidemiology of breast cancer

DPJ: Whitehead Biomedical Research Building, 615 Michael St, Room 205P

Atlanta, GA, 30322. Phone: 404-727-5970. Fax: 404-727-2974. E-mail: dpjones@emory.edu

BC: 1683 Shattuck Avenue, Suite B, Berkeley, CA 94709. E-mail: bcohn@chdstudies.org

[†]Corresponding authors:

Author Contributions

1

6

7

- Designed research YMG, PC, DPJ, BC
- Performed research YMG, NK, VL, GS
- Analyzed data YMG, JW, ST, PC, NK, GS, DPJ, BC
- Wrote the paper YMG, ST, NK, PC, DPJ, BC

Declaration of Competing Financial Interests

8 The authors declare they have no actual or potential competing financial interests.

ABSTRACT

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

Breast cancer is now the most common cancer globally, accounting for 12% of all new annual cancer cases worldwide. Despite epidemiologic studies having established a number of risk factors, knowledge of chemical exposure risks is limited to a relatively small number of chemicals. In this exposome research study, we used non-targeted, high-resolution mass spectrometry (HRMS) of pregnancy cohort biospecimens in the Child Health and Development Studies (CHDS) to test for associations with breast cancer identified via the California Cancer Registry. Second (T2) and third (T3) trimester archival samples were analyzed from 182 women who subsequently developed breast cancer and 384 randomly selected women who did not develop breast cancer. Environmental chemicals were annotated with the Toxin and Toxin-Target Database (T3DB) for chemical signals that were higher in breast cancer cases and used with an exposome epidemiology analytic framework to identify suspect chemicals and associated metabolic networks. Network and pathway enrichment analyses showed consistent linkage in both T2 and T3 to inflammation pathways, including linoleate, arachidonic acid and prostaglandins, and identified new suspect environmental chemicals associated with breast cancer, i.e., an N-substituted piperidine insecticide and a common commercial product, 2,4dinitrophenol (DNP), linked to variations in amino acid and nucleotide pathways in T2 and benzo[a]carbazole and a benzoate derivative linked to glycan and amino sugar metabolism in T3. The results identify new suspect environmental chemical risk factors for breast cancer and provide an exposome epidemiology framework for discovery of suspect environmental chemicals and potential mechanistic associations with breast cancer.

Keywords: Cancer, exposome, metabolomics, pregnancy

Abbreviations

- BC, breast cancer; FDR, false discovery rate; HRM, high-resolution metabolomics; HRMS,
- high-resolution mass spectrometry; LC-HRMS, liquid chromatography-high resolution mass
- spectrometry; MWAS, metabolome-wide association study; m/z, mass to charge; RT, retention
- time; T2, second trimester; T3, third trimester, T3DB, the toxin and toxin-targeted database.

1. Introduction

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

High-resolution metabolomics (HRM) uses advanced mass spectrometry and data science for non-targeted analysis of biological samples to obtain insight into an individual's metabolism along with the individual's exposome, including chemicals derived from diet, intestinal microbiome, dietary supplements, pharmaceuticals, personal use products and environmental exposures (Jones et al. 2012). The metabolome is a functional readout of the interactions of a person's genes with exposures from diet and environment (Johnson et al. 2017; Jones et al. 2016; Niedzwiecki et al. 2019) and has been used extensively in combination with exposure measurements, such as air pollution (Liang et al. 2018; Ritz et al. 2022) and targeted environmental chemicals, such as DDT, PCBs and PBB (Hu et al. 2020; Walker et al. 2019), to gain understanding of functional associations with exposures. Use in a non-targeted manner for discovery of new chemical associations with disease, however, are limited. A vision for development of exposome epidemiology, i.e., using omics scale biomonitoring for disease epidemiology, is available (Jones and Cohn 2020). The current study was undertaken to apply exposome epidemiology concepts for discovery of potential new environmental factors contributing to breast cancer. The long-term goal for complex diseases such as breast cancer, which involves multiple genetic, behavioral and environmental factors, is to integrate omics scale biomonitoring with other factors to ultimately improve prediction and intervention strategies to decrease disease burden. To perform a non-targeted exposome-wide association study of breast cancer, we used archival blood samples from the, Child Health and Development Studies (CHDS) cohort collected during pregnancy from 1959-1967. Second (T2) and third (T3) trimester archival

samples, collected from 1959-1967, of 182 women who subsequently developed breast cancer, were compared to those from 384 women who did not develop breast cancer.

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

We developed an exposome epidemiology approach (Fig 1) in which we first performed non-targeted statistical analysis to select HRM features that were higher in cases than in noncases. In this selection, we use raw p<0.05 as a cutoff for selection based upon the expectation that multiple environmental factors with small effect size may contribute to breast cancer, and this more liberal selection criteria is more appropriate for a small-population discovery study because it provides a better balance between Type 1 and Type 2 statistical error than more rigorous False Discovery Rate (FDR) criteria. We selected HRM features that were higher in cases than non-cases to search for potentially causative factors by matching to a xenobiotic database, Toxin and Toxin-Target Database (T3DB) (Lim et al. 2010; Wishart et al. 2015), recognizing that protective factors that are decreased in association with breast cancer would prioritize use of HRM features that were lower in cases and an alternative database, such as Food Database (FoodDB) (Scalbert et al. 2011). HRM features that were increased with breast cancer and annotated as environmental chemicals were then used for network analysis with the datadependent community detection tool, xMWAS (Uppal et al. 2018). Pathway enrichment analysis of the most central communities was then performed with *mummichog* (Li *et al.* 2013), and targeted mass spectrometry was used to improve understanding of the annotated chemicals associated with breast cancer outcome. The results provide evidence for new candidate environmental breast carcinogens and information concerning possible mechanisms by which these agents contribute to breast cancer.

2. Materials and methods

2.1 Samples and Assays

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

The CHDS recruited women residing in the Oakland and East Bay, California area who were members of the Kaiser Foundation Health Plan and received obstetric care for pregnancies between 1959 and 1966 with deliveries extending into 1967 (van den Berg et al. 1988). More than 98% of all eligible women enrolled. Blood samples were collected from these mothers during pregnancy in each trimester and in the early post-partum period, processed to isolate serum, and stored since then at -20° Celsius. Second and third trimester archival samples available were analyzed for HRM and environmental chemicals. The samples used for the present study include second (T2, n=182)) and third (T3, n=172)) trimester archival samples of 201 women who subsequently developed breast cancer, compared to second (T2, n=384) and third (T3, n=351) trimester archival samples from 413 women who did not develop breast cancer. Breast cancer cases were identified by linkage to the California Cancer Registry for cases diagnosed through 1997. Record abstraction for cancer diagnoses to the California Cancer Registry is based primarily on pathology reports, and case identification is considered to be >99% complete after a 2-year lag (Perkins et al.). Cases were defined as mothers with incident invasive or noninvasive breast cancer diagnosed at a median age at diagnosis of 54 years (interquartile range, 13 years) with available prenatal serum and a standardized gross placental exam. Non-cases were an 8% sample of women not known to have breast cancer randomly selected among mothers with available prenatal serum and a standardized gross placental exam (Cohn et al. 2017). Breast cancer rates for included and excluded subsets in the CHDS cohort were highly comparable suggesting selection did not impose significant bias: 1.89 per 1,000 person-years (95% Confidence Interval ([95% CI] = 1.60,

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

2.23) for included vs. 1.88 per 1,000 (95% CI=1.59, 2.20) for excluded. It is possible, however, that we missed some cases of breast cancer, including among women who are identified in this study as "non-cases". In this case, failure to identify cases among the non-case group would result in underestimating differences between cases and non-cases in these analyses and would not be expected to impact findings. The CHDS founding mothers voluntarily participated in an in-person interview and gave permission to access their own medical records and those of their children to researchers. The institutional review board of the Public Health Institute approved the present study (IRB#120-002), and we complied with all federal guidelines governing the use of human participants. Forty-six percent of cases and forty-five percent of the non-cases had available data and serum. 2.2 Chemicals HPLC grade acetonitrile and methanol, LC-MS water and 98% formic acid were obtained from Sigma-Aldrich (St. Louis, MO). A mixture of 14 stable isotopic chemicals were used as an internal standard (Go et al. 2015) included [13C₆]-D-glucose, [15N]-indole, [2-15N]-L-lysine dihydrochloride, [13C₅]-L-glutamic acid, [13C₇]-benzoic acid, [3.4-13C₂]-cholesterol, [15N]-Ltyrosine, [trimethyl- 13 C₃]-caffeine, [15 N₂]-uracil, [3,3- 13 C₂]-cystine, [1,2- 13 C₂]-palmitic acid, [15N, 13C₅]-L-methionine, [15N]-choline chloride and 2'-deoxyguanosine-15N₂ 13C₁₀-5'monophosphate from Cambridge Isotope Laboratories, Inc (Andover, PA). 2.3 High-resolution mass spectrometry. Serum samples were analyzed with liquid chromatography-high resolution mass spectrometry (LC-HRMS) as described previously (Jarrell et al. 2021; Jarrell et al. 2020). Briefly, 50 µL of serum was treated 2:1 (v/v) with acetonitrile,

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

and 2.5 µL of the stable isotope standard mixture was added. Proteins were precipitated by incubation at 4°C for 30 min and removed by centrifugation for 10 min at 21000 x g at 4°C. Supernatants were placed in autosampler vials and maintained at 4°C in an autosampler until analysis. Two pooled human reference samples including NIST SRM1950 and Ostd [pooled plasma from 2 separate lots from Equitech-Bio, Inc (Kerrville, Texas)] were included. NIST SRM1950 was run at the beginning and end of the full sample set, and Qstd was included at the beginning and end of each batch of 20 samples. Samples and reference materials were analyzed with three technical replicates using a High-Field Q-Exactive mass spectrometer (Thermo Fisher) with C18 chromatography and electrospray ionization (ESI) in negative mode. Data collection occurred continuously throughout 5 min of chromatographic separation from 85 to 1,275 mass-to-charge ratio (m/z). Data extraction was performed using apLCMS and xMSanalyzer, generating mass spectral features consisting of m/z, retention time (RT) and peak intensity. Feature and sample filtering retained features with a median CV of 50% or less, a minimum mean Pearson correlation coefficient of 0.7 between technical replicates of each sample, and presence in at least 30% of samples. 2.4 Selection of features associated with subsequent breast cancer. A Metabolome-Wide Association Study (MWAS) was used to identify m/z features associated with breast cancer outcome. Intensity values were log2 transformed, and LIMMA was performed using the R package, xmsPANDA (https://github.com/kuppal2/xmsPANDA), with retention of features at raw *p*<0.05.

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

2.5 Annotation of Mass Spectral Features and Metabolite Identification. To select mass spectral features of environmental interest, features positively associated with subsequent breast cancer diagnosis were subjected to a multistage clustering algorithm and annotated with xMSannotator (Uppal et al. 2017) using T3DB (Lim et al. 2010; Wishart 2015) at 5 ppm tolerance. For selected chemicals, identities were confirmed when possible by accurate m/z match, co-elution with authentic standards and ion dissociation mass spectrometry (MS/MS); Level 1 identification by criteria of Schymanski et al (Schymanski et al. 2014)]. 2.6 Targeted mass spectrometry analysis in identification of features. Annotated chemicals at the center of the xMWAS network structures underwent additional investigation by ion fragmentation, structure analysis, and spectral matching to publicly available spectral libraries. Plasma samples with the highest intensities of the chemicals of interest were selected and analyzed with C18 liquid chromatography (Dionex Ultimate 3000) and MS² ion fragmentation (Thermo Scientific Fusion) with negative ESI. The mass spectrometer was set to scan a minimal range of m/z's at 60k resolution for MS^1 . Then, an inclusion list isolated the m/z of interest. MS^2 fragmentation was acquired in HCD mode with a normalized collision energy of 30% and analyzed at 30,000 resolution using the dual-pressure linear ion trap. Raw MS¹ and MS² spectra were analyzed in xCalibur QualBrowser (Thermo). Fragmentation patterns were analyzed with ChemDraw (PerkinElmer Informatics) and compared against experimental spectra in the MassBank of North America (MoNA) library. MoNA MS² spectra were selected for negative ESI and similar collision energy. When MoNA spectra were not available, experimental spectra were searched against the NIST Tandem Mass Spectral Library, which provides a spectral match percentage but no information on collision energy or ionization polarity. To align with the goal of high-

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

throughput analyses, chromatographic gradients and fragmentation settings were maintained to be consistent with the original analysis and not extensively optimized for each chemical. Under these conditions, the complexity of the plasma sample matrix and the low abundance of environmental chemicals does not allow for the isolation of one precursor and its fragments. Therefore, in some spectra, the precursor mass is easily visible within 10 ppm error, but the fragments are not clearly visible due to interference from other ions. Spectral peaks corresponding to fragments were identified by their theoretical structures in "ChemDraw" with unit resolution in the dual-pressure linear ion trap detector. 2.7 Network and Pathway Analyses. Annotated environmental chemicals were tested for associations with m/z features using xMWAS based on partial least-squares regression (Uppal et al. 2018). Thresholds for inclusion in the networks were |r| > 0.30 and p < 0.05. Pairwise results from MWAS of the metabolites used for generation of network structures were used for pathway enrichment analysis using mummichog (v3) (Li et al. 2013). Enriched pathways were filtered for those that included at least 3 significantly associated metabolites at p < 0.05.

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

3. RESULTS 3.1 Study population demographics T2 and T3 samples were available from 201 individuals who subsequently developed breast cancer. These individuals had a median age of 31 y at time of blood collection, and the individuals without breast cancer had a median age of 36 (p<0.0001). Serum collection occurred between 1960 and 1964, with T2 blood collection occurring at a median gestational age of 161 and 160 days in cases and non-cases, respectively. For T3, blood collections were at a median gestational age of 249 and 250 days, respectively. Characteristics of cases and non-cases are provided in **Table 1**. 3.2 Metabolic feature profiling on T2 and T3 serum To select m/z features which were positively associated with subsequent breast cancer diagnosis, we retained 9042 m/z features present in at least 80% of samples for statistical analyses and selection of features for annotation. For T2 and T3 measurements, no features had FDR<0.05 and therefore none are likely to be useful biomarkers for breast cancer risk. Any of the m/zfeatures selected with raw p<0.05 could contribute to breast cancer risk, and 521 features had p<0.05 for T2, and 557 features had p<0.05 for T3. Of these m/z features, 188 were higher in breast cancer than non-cases in T2 samples while 151 were higher in breast cancer than noncases in T3 samples (**Table 2**). These positively associated m/z features were selected to search for possible matches to environmental chemicals.

3.3 Environmental chemical annotation of suspect chemicals in breast cancer group

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

Most of the selected m/z features are likely to represent endogenous metabolites, but environmental chemicals contributing to subsequent breast cancer could also be present. To search for suspect environmental chemicals associated with subsequent breast cancer diagnosis, we used xMSannotator, a network-based computational tool, with the Toxin and Toxin-Target Database, T3DB (Wishart 2015; Wishart et al. 2007), to further characterize the mass spectral features which were higher in their intensities in women who went on to develop breast cancer. xMSannotator uses a multistage clustering algorithm in which intensity profiles, retention time characteristics, mass defect, and isotope/adduct patterns are used to assign confidence levels to annotation results relative to publicly available databases, such as T3DB. The annotated environmental chemicals for T2 and T3 are shown in **Table 3** and **Table 4**, respectively. More environmental chemicals were annotated in T2 than T3 serum, yielding 17 and 7, respectively, and these included matches to chemicals widely used for anti-inflammatory, anticonvulsant and antipsychotic drugs, quaternary ammonium salt, pesticides, herbicides, fungicides, plasticizers, preservatives, cleaning materials, and flavorings. Importantly, at this level of investigation, these annotations are only suspect chemicals and require further investigation and verification (see below). The magnitude of difference was between 10% and 30% higher in women who went on to develop breast cancer compared to those who did not ($p \le 0.05$, Tables 3 and 4). 3.4 Metabolome-Wide Association Study (MWAS) of T2 Environmental Chemicals Prior studies have identified inflammatory lipid pathways (linoleate, arachidonate, prostaglandin), lipid and energy metabolism pathways (fatty acids, TCA cycle), oxidative stress pathways (methionine and cysteine), and nitrogen metabolism pathways (urea cycle, pyrimidine, purine) as top metabolic pathway associations with environmental chemicals and breast cancer

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

(Hu et al. 2019; Li et al. 2020; Walker et al. 2019). To determine whether the features annotated as environmental chemicals (Table 3) are associated with changes in metabolites and metabolic pathways, we used data-driven integration and network analysis of the T3DB annotated features and all 9042 extracted metabolic signals, with xMWAS (Uppal et al. 2018). As shown in Fig 2, network analysis showed three metabolic communities, Community 1 (C1, orange), Community 2 (C2, blue) and Community 3 (C3, green). C1 was positively associated with m/z 315.1957 (F1, Fig 2, Table 3). We performed metabolic pathway enrichment analysis (Fig 3) on the 716 metabolic features associated with C1 using the *mummichog 3* software (Li et al. 2013). Associated pathways included linoleate, arachidonate and prostaglandins (Fig 3A), which are closely related to inflammation and oxidative stress. Database searches showed that m/z315.1957 matched multiple lipids (e.g., prostaglandins, resolvins), consistent with the strong associations with related lipid species having activities in inflammation. The vitamin A pathway was also associated with C1 (Fig 3A), and targeted mass spectrometry with MS/MS analysis showed a likelihood that m/z 315.1957 was 4-hydroxyretinoic acid (**F1, Supplemental Fig. S1**). C1 extensively overlapped with Community 2 (C2, blue), which was positively associated with m/z 334.2090 (F2, Fig 2, Table 3). In addition to pathway associations with prostaglandins, linoleic acid and arachidonic acid, a subset of C2 included phospholipids, e.g., sphingosine, phosphatidyl choline (PC), and triglyceride (blue, Fig 2), associated with glycerophospholipid metabolism. Thus, this chemical defines a separate cluster of metabolites associated with breast cancer than those in C1, but this feature remains unidentified because subsequent mass spectrometry analysis failed to provide support for identification. Together, results from C1 and C2 support prior findings that inflammatory lipid and other lipid pathways associated with DDT,

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

PCB and PBB are associated with breast cancer, but do not reveal any new suspect environmental chemicals. A third community, C3, had metabolomic associations (green) which were separated from C1 and C2 and positively associated with m/z features annotated as environmental chemicals, including an insecticide (F3, nitromethylene-piperidine), a wood preservation and dye production chemical (F4, 2,4-dinitrophenol), oxalate (F5), and F6, m/z 156.0666 and F7, m/z 345.0777 (**Fig 2, Table 3**). Of these, oxalate was previously confirmed, and supportive targeted mass spectrometry data was obtained for 2-nitromethylene-piperidine and 2,4-dinitrophenol (F3 and **F5, Supplemental Fig. S1**). The m/z feature 156.0666 (F6) was present at high concentrations in most samples and appeared likely to be an endogenous metabolite, N-acetylproline (F6, **Supplemental Fig. S1**). No supportive mass spectrometry data could be obtained for the m/zfeature 345.0777 (F7). The 56 metabolic features in C3 that were positively associated with these annotated environmental chemicals were related to pathways for antioxidant methionine (Met) and cysteine (Cys) regulation, urea cycle, amino acids (glycine, serine, alanine, threonine, aspartate, asparagine, lysine), glycerophospholipids, and purine and pyrimidine nucleotide metabolism (Fig 3C). Representative metabolites associated with these pathways of each community are indicated next to each community (Fig 2) and included amino acids (glutamate, serine, lysine, aspartate), a pyrimidine (orotidine), a purine (uric acid), and a coenzyme for mitochondrial electron transfer and the TCA cycle (dihydrolipoamide). Collectively, the results for T2 serum of women who subsequently developed breast cancer show that two suspect environmental chemicals, nitromethylene-piperidine and 2,4-dinitrophenol, along with oxalate, are closely associated with metabolic perturbations related to amino acid and nucleotide

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

metabolism. Other communities included lipids functioning in inflammation, sphingolipids and lipids, but no suspect environmental chemicals were identified for these communities. 3.5 MWAS of T3 Environmental Chemicals and alterations in metabolic pathway Following the same experimental approach shown above, we examined the relationship of annotated matches of T3 suspect environmental chemicals (**Table 4**) and changes in metabolites using xMWAS (Uppal et al. 2018). Two major metabolic communities were identified (**Fig 4**), with the first community (labeled C4, orange) including metabolites associated exclusively with m/z 271.1195 (F18) and second community (C5, blue) including metabolites associated with m/z214.9728 (F19), m/z 217.0866 (F20) and m/z 215.0327 (F21) (**Fig 4**). Targeted mass spectrometry analysis of m/z 271.1195 (F18) showed that this feature was likely ergosterol or related derivative (F18, Supplemental Fig. S2). Pathway enrichment analysis of the 650 metabolic features of C4 showed associated pathways for arachidonate, leukotriene, linoleate, vitamin A, prostaglandins, vitamin E and steroid hormones (Fig 5A). Most of these pathways are closely related to inflammation and oxidative stress, as also found in T2 associations in C1 and C2 (Fig 3A, 3B). Targeted mass spectrometry analyses showed that m/z 214.9713 (F19) was likely a bromine adduct of a benzoic acid metabolite (F19, Supplemental Fig. S2); m/z217.0866 (F20) had an MS² spectrum with 83% match to benzo[a]carbazole (**F20**, Supplemental Fig. S2); m/z 215.0327 (F21) was a high abundance signal from glucose (F21, **Supplemental Fig. S2**). Pathway enrichment analysis of the 155 metabolic features in C5 showed associations for sialic acid, pentose phosphate, N-glycan degradation, galactose, phosphatidylinositol, glycolysis and gluconeogenesis, butanoate, and glycosphingolipid pathways (Fig 5B). Representative metabolites associated with these pathways are indicated next

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

to each community (Fig 4). Collectively, suspect environmental chemicals in Communities 4 and 5 include a benzoate derivative and benzo[a]carbazole, and metabolic pathway associations suggesting that breast cancer effects could be mediated through inflammatory lipids, glucoserelated metabolism and estrogenic signaling. 3.6 Comparisons of T2 and T3 suspect chemical-metabolic pathway associations In comparison of findings for T3 and T2, metabolic pathways for C4 in T3 showed considerable overlap with the pathways associated with C1 and C2 in T2. In contrast, the remaining community, C5, in T3 differed substantially from the remaining community, C3, in T2. Specifically, in T3, we identified a suspect benzoate and benzo[a]carbazole in breast cancer cases that were associated with pathways of carbohydrate metabolism functioning in extracellular matrix turnover and complex carbohydrate metabolism. In T2, we identified a suspect insecticide, 2-nitromethylpiperidine, a widely used commercial chemical, 2,4dinitrophenol, and oxalic acid, in breast cancer cases that were associated with central pathways functioning in amino acid homeostasis, urea cycle, pyrimidine and purine metabolism, and defense against oxidative stress.

4. Discussion

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

The present study applies a new exposome epidemiology approach to discover suspect environmental chemicals that may be implicated in breast cancer development. New suspect chemicals from this analysis include an insecticide, nitromethylene-piperidine; a common commercial chemical, 2,4-dinitrophenol; a heterocyclic amine with diverse commercial applications, benzo[a]carbazole; a benzoate derivative which could be derived from natural products or environmental chemicals; and oxalate, an endogenous metabolite that is also used as a cleaning agent. These chemicals were at higher abundance in serum of women decades before breast cancer diagnosis. Importantly, the network analysis is data-dependent, raising the possibility that individual chemicals could have a causal role in breast cancer or that breast cancer could occur through interaction of multiple chemicals in causal mechanisms. In the latter case, individual variations in exposure could have important impact on risk. New approaches to identify suspect carcinogens are critical because research over the last 50 years has not translated to a strategy for individual breast cancer prevention. The suspect chemical signal F18 (m/z 271.1195) in Community 4, was consistent with identification as ergosterol, which is derived from yeast and precursor of vitamin D2. Pathway mapping of this community showed overlap with inflammatory lipid pathways found in Communities 1 and 2, and also included vitamin A metabolism, which is consistent with feature F1 in Community 1, 4hydroxyretinoic acid, being a suspect chemical. Many diet-derived carotenoids can be converted to isobaric species to 4-hydroxyretinoic acid, and these are not distinguished by the HRM methods used. Thus, future research will be needed to address the potential for diet-environment interactions, such as implied by the overlap of estrogen-, vitamin D- and vitamin A-linked

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

metabolites. Pregnancy impacts initiation, progression, and susceptibility to breast cancer (Troisi et al. 2018), and therefore pregnancy provides an appropriate time frame for study. Later age at pregnancy is a long-established breast cancer risk factor (Albrektsen et al. 2005; MacMahon et al. 1970) which has become increasingly common and is still unexplained. Because first birth rates have increased 6-fold for women ages 35-39 from 1973-2006 (Martin et al. 2015), more detailed understanding of the respective contributions and interactions must be a priority to learn how to mitigate risk for this population group of higher risk women. In T2, an additional chemical cluster containing an insecticide (nitromethylene-piperidine), a cleaning agent (oxalate), a chemical used in wood preservation and dye production (dinitrophenol), and two unidentified chemical features (F2, F7), were associated with multiple amino acid pathways and nitrogen metabolism (urea cycle, pyrimidine, purine). The amino acid pathways overlap with pathways previously found to vary with persistent organic pollutants, p,p'-DDT (Hu et al. 2020) and PBBs (Walker et al. 2019). In a multigenerational study, p,p'-DDT exposure in women before puberty was found to be associated with breast cancer in mothers (Cohn et al. 2007) and in utero o',p'-DDT exposure was associated with breast cancer in daughters (Cohn et al. 2015). Polybrominated biphenyls (PBB) are also persistent organic pollutants that cause breast cancer (IARC 2015). Potential mechanistic connections between dintrophenol, nitromethylene-piperidine, oxalate, and these POPs are not apparent, and mechanisms by which POPs disrupt central amino acid and nitrogen metabolism pathways are not known. In particular, amino acids are essential for growth and development, and disruption of pyrimidine and purine metabolism can be expected to have long-term consequences on

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

metabolic programming which could contribute to cancer susceptibility. Thus, these findings warrant further investigation into underlying mechanisms related to breast cancer development. In T3, the large metabolic community (C4, Fig 4) containing inflammatory lipids was linked to a sparse community (C5, Fig 4) containing glucose, benzo[a]carbazole and a suspect benzoate derivative. Of potential importance in this network, the glucose signal was negatively associated with metabolites connected to sialic acid, N-glycan and other pathways associated with extracellular matrix and turnover of connective tissue. Benzoate is conjugated with glycine for elimination, and the role of glycine in folate-dependent metabolism through the vitamin B₆dependent hydroxymethyltransferase raises the possibility that benzoate derivatives could have unrecognized pathogenic effects. Similarly, the heterocyclic amine, benzo[a]carbazole, could be bioactivated by Cyp enzymes to generate mutagenic species which have not been characterized. Future hypothesis-driven research will be needed to address these possibilities. The exposome epidemiology approach used in the present study has important assumptions, i.e., that chemical exposures which increase cancer risk can occur decades before breast cancer occurrence, that these exposures are detectable and at higher abundance in serum decades prior to breast cancer detection, and that network analyses of HRM data are sufficient to detect these exposures and link them to biologic responses. With these assumptions, all HRM features from archival blood serum of women collected decades before breast cancer diagnosis can be used in a non-targeted manner to select ones that are increased (p<0.05) in association with breast cancer occurrence. This selection criterion is not suitable for biomarker development because of multiple testing; however, this cutoff is suitable for discovery of potential chemical risk factors

because any of the features at this cutoff could be correct. The selected HRM features are then used with a toxic exposome database, T3DB, to obtain accurate mass matches to known toxic chemicals, and these are subjected to non-targeted network and pathway enrichment analyses to identify environmental chemical-metabolic network associations linked to breast cancer outcome.

Exposome epidemiology will benefit from populations of tens or hundreds of thousands of individuals by enabling detection of exposures impacting small numbers of women and/or having only small contributions individually to breast cancer risk. The present study with only hundreds rather than thousands of individuals has limited capability to detect carcinogens with small effect size. Additionally, selection of HRM features for statistical selection in the current study required that features be present in 80% of the samples. Environmental chemicals and personal use products such as hair dyes cannot be expected to be present in 80% of the women and unlikely to be detectable. Application of untargeted gas chromatography-high-resolution mass spectrometry, which provides capabilities to measure other hydrophobic and volatile environmental chemicals (Hu *et al.* 2021), can be used to enhance coverage of environmental chemicals. Thus, future studies will benefit from larger population sizes, inclusion of complementary chemical analyses, and use of statistical methods which can accommodate sparse environmental chemical detection.

5. Conclusion

Recent technological and statistical advances in high-resolution metabolomics (HRM) provide capabilities for omics scale biomonitoring of chemicals derived from the environment along with

endogenous metabolism and chemicals from the diet, intestinal microbiome, dietary supplements, pharmaceuticals, and personal use products. Because the metabolome is a functional readout of the interactions of a person's genes with exposures, HRM of biologic samples provides one of the most accessible ways to connect environmental exposures with biologic status to anticipate breast cancer. As shown in the present study, these can be used with network and pathway analysis to identify suspect environmental chemicals and functional communities linked to breast cancer outcome. Such network approaches can be broadly applied to discover how life-long exposures impact personal cancer risks. For breast cancer, we believe that this approach will yield critically needed protocols to enhance protection or mediate pregnancy-associated risk.

Funding: This study was supported by Department of Defense Grant W81XWH2010103, and National Institute of Environmental Health and Science grant R21 ES031824, R01 ES031980 and P30 ES019776.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

References Albrektsen, G.; Heuch, I.; Hansen, S.; Kvale, G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. British Journal of Cancer 2005;92:167-175 Cohn, B.A.; Cirillo, P.M.; Hopper, B.R.; Siiteri, P.K. Third Trimester Estrogens and Maternal Breast Cancer: Prospective Evidence. J Clin Endocrinol Metab 2017;102:3739-3748 Cohn, B.A.; La Merrill, M.; Krigbaum, N.Y.; Yeh, G.; Park, J.S.; Zimmermann, L.; Cirillo, P.M. DDT Exposure in Utero and Breast Cancer. J Clin Endocrinol Metab 2015;100:2865-2872 Cohn, B.A.; Wolff, M.S.; Cirillo, P.M.; Sholtz, R.I. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect 2007;115:1406-1414 Go, Y.M.; Kim, C.W.; Walker, D.I.; Kang, D.W.; Kumar, S.; Orr, M.; Uppal, K.; Quyyumi, A.A.; Jo, H.; Jones, D.P. Disturbed flow induces systemic changes in metabolites in mouse plasma: a metabolomics study using ApoE(-)/(-) mice with partial carotid ligation. Am J Physiol Regul Integr Comp Physiol 2015;308:R62-72 Hu, X.; Li, S.; Cirillo, P.; Krigbaum, N.; Tran, V.; Ishikawa, T.; La Merrill, M.A.; Jones, D.P.; Cohn, B. Metabolome Wide Association Study of serum DDT and DDE in Pregnancy and Early Postpartum. Reprod Toxicol 2020;92:129-137 Hu, X.; Li, S.; Cirillo, P.M.; Krigbaum, N.Y.; Tran, V.; Jones, D.P.; Cohn, B.A. Metabolome Wide Association Study of Serum Poly and Perfluoroalkyl Substances (PFASs) in Pregnancy and Early Postpartum. Reprod Toxicol 2019;87:70-78

449 Hu, X.; Walker, D.I.; Liang, Y.; Smith, M.R.; Orr, M.L.; Juran, B.D.; Ma, C.; Uppal, K.; Koval, 450 M.; Martin, G.S.; Neujahr, D.C.; Marsit, C.J.; Go, Y.M.; Pennell, K.D.; Miller, G.W.; Lazaridis, K.N.; Jones, D.P. A scalable workflow to characterize the human exposome. 451 452 Nat Commun 2021;12:5575 IARC. Polychlorinated Biphenyls and Polybrominated Biphenyls ed^eds; 2015 453 454 Jarrell, Z.R.; Smith, M.R.; He, X.; Orr, M.; Jones, D.P.; Go, Y.M. Firsthand and Secondhand 455 Exposure Levels of Maltol-Flavored Electronic Nicotine Delivery System Vapors Disrupt Amino Acid Metabolism. Toxicol Sci 2021;182:70-81 456 457 Jarrell, Z.R.; Smith, M.R.; Hu, X.; Orr, M.; Liu, K.H.; Quyyumi, A.A.; Jones, D.P.; Go, Y.M. 458 Plasma acylcarnitine levels increase with healthy aging. Aging (Albany NY) 2020;12:13555-13570 459 460 Johnson, C.H.; Athersuch, T.J.; Collman, G.W.; Dhungana, S.; Grant, D.F.; Jones, D.P.; Patel, C.J.; Vasiliou, V. Yale school of public health symposium on lifetime exposures and 461 human health: the exposome; summary and future reflections. Human genomics 462 2017;11:32 463 Jones, D.P.; Cohn, B.A. A vision for exposome epidemiology: The pregnancy exposome in 464 relation to breast cancer in the Child Health and Development Studies. Reprod Toxicol 465 2020;92:4-10 466 Jones, D.P.; Park, Y.; Ziegler, T.R. Nutritional metabolomics: progress in addressing complexity 467 468 in diet and health. Annu Rev Nutr 2012;32:183-202 Jones, D.P.; Walker, D.I.; Uppal, K.; Rohrbeck, P.; Mallon, C.T.; Go, Y.M. Metabolic Pathways 469 470 and Networks Associated With Tobacco Use in Military Personnel. Journal of 471 occupational and environmental medicine 2016;58:S111-116

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

Li, S.; Cirillo, P.; Hu, X.; Tran, V.; Krigbaum, N.; Yu, S.; Jones, D.P.; Cohn, B. Understanding mixed environmental exposures using metabolomics via a hierarchical community network model in a cohort of California women in 1960's. Reprod Toxicol 2020;92:57-65 Li, S.; Park, Y.; Duraisingham, S.; Strobel, F.H.; Khan, N.; Soltow, Q.A.; Jones, D.P.; Pulendran, B. Predicting network activity from high throughput metabolomics. PLoS Comput Biol 2013;9:e1003123 Liang, D.; Moutinho, J.L.; Golan, R.; Yu, T.; Ladva, C.N.; Niedzwiecki, M.; Walker, D.I.; Sarnat, S.E.; Chang, H.H.; Greenwald, R.; Jones, D.P.; Russell, A.G.; Sarnat, J.A. Use of high-resolution metabolomics for the identification of metabolic signals associated with traffic-related air pollution. Environ Int 2018;120:145-154 Lim, E.; Pon, A.; Djoumbou, Y.; Knox, C.; Shrivastava, S.; Guo, A.C.; Neveu, V.; Wishart, D.S. T3DB: a comprehensively annotated database of common toxins and their targets. Nucleic Acids Res 2010;38:D781-786 MacMahon, B.; Cole, P.; Lin, T.M.; Lowe, C.R.; Mirra, A.P.; Ravnihar, B.; Salber, E.J.; Valaoras, V.G.; Yuasa, S. Age at first birth and breast cancer risk. Bull World Health Organ 1970;43:209-221 Martin, J.; Hamilton, B.; Osterman, M.; Curtin, S.; Matthews, T. Births: final data for 2013. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2015;64:1 Niedzwiecki, M.M.; Walker, D.I.; Vermeulen, R.; Chadeau-Hyam, M.; Jones, D.P.; Miller, G.W. The Exposome: Molecules to Populations. Annu Rev Pharmacol Toxicol 2019;59:107-127

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

Perkins, C.; Wright, W.; Schlag, R. Cancer Incidence and Mortality in California, 1988-1994, CA: California Department of Health Servicies, Cancer Surveilance Section. Ritz, B.; Yan, Q.; He, D.; Wu, J.; Walker, D.I.; Uppal, K.; Jones, D.P.; Heck, J.E. Child serum metabolome and traffic-related air pollution exposure in pregnancy. Environ Res 2022;203:111907 Scalbert, A.; Andres-Lacueva, C.; Arita, M.; Kroon, P.; Manach, C.; Urpi-Sarda, M.; Wishart, D. Databases on food phytochemicals and their health-promoting effects. J Agric Food Chem 2011;59:4331-4348 Schymanski, E.L.; Jeon, J.; Gulde, R.; Fenner, K.; Ruff, M.; Singer, H.P.; Hollender, J. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol 2014;48:2097-2098 Troisi, R.; Bjørge, T.; Gissler, M.; Grotmol, T.; Kitahara, C.M.; Myrtveit Saether, S.; Ording, A.G.; Sköld, C.; Sørensen, H.T.; Trabert, B. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med 2018;283:430-445 Uppal, K.; Ma, C.; Go, Y.M.; Jones, D.P.; Wren, J. xMWAS: a data-driven integration and differential network analysis tool. Bioinformatics 2018;34:701-702 Uppal, K.; Walker, D.I.; Jones, D.P. xMSannotator: An R Package for Network-Based Annotation of High-Resolution Metabolomics Data. Anal Chem 2017;89:1063-1067 van den Berg, B.J.; Christianson, R.E.; Oechsli, F.W. The California Child Health and Development Studies of the School of Public Health, University of California at Berkeley. Paediatr Perinat Epidemiol 1988;2:265-282

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

Walker, D.I.; Marder, M.E.; Yano, Y.; Terrell, M.; Liang, Y.; Barr, D.B.; Miller, G.W.; Jones, D.P.; Marcus, M.; Pennell, K.D. Multigenerational metabolic profiling in the Michigan PBB registry. Environ Res 2019;172:182-193 Wilkinson, M.D.; Dumontier, M.; Aalbersberg, I.J.; Appleton, G.; Axton, M.; Baak, A.; Blomberg, N.; Boiten, J.W.; da Silva Santos, L.B.; Bourne, P.E.; Bouwman, J.; Brookes, A.J.; Clark, T.; Crosas, M.; Dillo, I.; Dumon, O.; Edmunds, S.; Evelo, C.T.; Finkers, R.; Gonzalez-Beltran, A.; Gray, A.J.; Groth, P.; Goble, C.; Grethe, J.S.; Heringa, J.; t Hoen, P.A.; Hooft, R.; Kuhn, T.; Kok, R.; Kok, J.; Lusher, S.J.; Martone, M.E.; Mons, A.; Packer, A.L.; Persson, B.; Rocca-Serra, P.; Roos, M.; van Schaik, R.; Sansone, S.A.; Schultes, E.; Sengstag, T.; Slater, T.; Strawn, G.; Swertz, M.A.; Thompson, M.; van der Lei, J.; van Mulligen, E.; Velterop, J.; Waagmeester, A.; Wittenburg, P.; Wolstencroft, K.; Zhao, J.; Mons, B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 2016;3:160018 Wishart, D.; Arndt, D.; Pon, A.; Sajed, T.; Guo, A.C.; Djoumbou, Y.; Knox, C.; Wilson, M.; Liang, Y.; Grant, J.; Liu, Y.; Goldansaz, S.A.; Rappaport, S.M. T3DB: the toxic exposome database. Nucleic Acids Res 2015;43:D928-934 Wishart, D.S. Identifying putative drug targets and potential drug leads: starting points for virtual screening and docking. Methods Mol Biol 2015;1215:425-444 Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M.A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.; Amegbey, G.; Block, D.; Hau, D.D.; Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G.E.; Macinnis, G.D.; Weljie, A.M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner,

R.; Li, L.; Marrie, T.; Sykes, B.D.; Vogel, H.J.; Querengesser, L. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007;35:D521-526 **Figure 1.** Exposome Epidemiology Workflow. The steps used in the current analysis are

Figure Legends

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

summarized in general form. In the first step, the study population and sample types can be selected for diverse purposes. In the second step, liquid chromatography, gas chromatography or other separation methods can be used with high-resolution mass spectrometry to generate tens of thousands of mass spectral features. For this purpose, multiple data extraction tools are available, and extraction parameters and filtration criteria can be selected to increase stringency or leniency in feature retention. For the third step, directionality of change is selected for features expected to have a causal or protective activity. For the fourth step, selected features are annotated using a relevant database. In the fifth step, selected and annotated features are used with network analysis to identify associated communities of mass spectral features. The sixth step applies pathway enrichment analysis to the associated communities of mass spectral features to characterize the associated biologic response. Finally, targeted mass spectral analysis of relevant mass spectral features provides prioritization for subsequent hypothesis-driven research to verify environmental chemical associations and underlying causal mechanisms. Figure 2. Metabolome-Wide Association Study (MWAS) of T3DB-annotated chemicals higher in second trimester (T2) serum. Association of seventeen T3DB-annotated features (Table 3) that are higher in breast cancer than non-cases with the metabolome (9,042 metabolic features) from T2 serum (n=384 for non-cases, n=182 for breast cancer) are examined using xMWAS. The outcome of xMWAS analysis is visualized with two separate networks at $|r| \ge 0.3$. The networks include three communities (C1, C2, C3) and show central seven chemicals (F1-F7) with tight

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

connections [C1 (orange), C2 (blue), C3 (green)]. Representative metabolites of pathways associated with community are shown next to each community. DHET: dihydroxyeicosatrienoic acid, EETA: epoxyeicosatrienoic acid, TG: triglyceride, PC: phosphatidylcholine. **Figure 3.** Metabolic pathway associated with second trimester (T2) chemicals. Pathway enrichment analysis with metabolites of three network communities in Fig. 2 was conducted using mummichog. A) A total of seven pathways were found altered with m/z 315.1957 (F1) in C1, B) Eight pathways were altered with m/z 334.2090 (F2) in C2, and C) Seven pathways were altered with environmental chemicals and drug metabolites (F3-F7) (p < 0.05). The ratio of selected metabolites mapped to the listed pathway over the number of total pathway metabolites detected is provided to the right of each bar. Figure 4. Metabolome-Wide Association Study (MWAS) of T3DB-annotated chemicals higher in third trimester (T3) serum. Association of seven T3DB-annotated chemicals (Table 4) that are higher in breast cancer than non-cases with the metabolome (9,042 metabolic features) from T3 serum (n=351 for non-cases, n=172 for breast cancer) are examined using xMWAS. The network is visualized at $|\mathbf{r}| \ge 0.3$ and includes two communities (C4 and C5) showing central four chemicals with tight connections [C4 (orange)] than C5 (blue)]. Representative metabolites of pathways associated with community are shown next to each community. Figure 5. Metabolic pathway associated with T3 chemicals. Pathway enrichment analysis with metabolites of two network communities in Fig. 4 was conducted using mummichog. A) Seven pathways were found altered with F18 chemical in C1 and B) eight pathways were altered with

chemicals (F19-F21) in C2 (p < 0.05). The ratio of selected metabolites mapped to the listed pathway over the number of total pathway metabolites detected is provided to the right of each bar.

Table 1. Characteristics of Study Population

	Non-Cases (N=413)		Cases (N=201)	
Characteristic	Median	(IQR)	Median	(IQR)
Year of mother's birth	1936	(9)	1931	(11)
Year of blood draw	1962	(2)	1962	(2)
Gestational day of T2 blood draw	160	(33)	161	(29)
Gestational day of T3 blood draw	250	(17)	249	(16)
BMI at first prenatal visit (kg/m ²) ^a	22.1	(4.3)	22.6	(4.2)
Characteristic	Percent		Percent	
Race		_		
non-Hispanic Caucasian	70		69	
African American	20		19	
Hispanic	2		1	
Asian	6		7	
Mixed	2		3	

Table 2. HRM profiling of T2 and T3 serum samples comparing breast case and non-case

groups ($P \le 0.05$). BC, breast cancer.

591

	T2 (182 BC, 384 non-	T3 (172 BC, 351 non-		
	cases)	cases)		
Total number of metabolic features	9042	9042		
Features differing at. <i>p</i> <0.05	521	557		
Differing features with BC/non-cases	188	151		
ratio > 1.0				

Table 3. T3DB-annotated m/z features higher in T2 serum of women who subsequently developed breast cancer (BC) compared with non-cases ($P \le 0.05$). Targeted mass spectrometry analysis was performed to aid in identification of features F1 to F7 which were found to occur in central communities of Fig 2, indicated by asterisk (*). T3DB annotations are provided for others (F8-F17).

Feature	Name	m/z	RT (sec)	% Higher in BC	Category
F1*	4-Hydroxyretinoic acid	315.1957	177	20	Vitamin A metabolite
F2*	Unidentified	334.2090	125	20	Unidentified
F3*	2-Nitromethylene- piperidine	141.0670	278	10	Insecticide
F4*	2,4-Dinitrophenol	183.0046	283	10	Multiple commercial uses
F5*	Oxalic Acid	88.9883	129	10	Cleaning agent
F6*	N-acetyl-proline	156.0666	283	10	Endogenous metabolite
F7*	Unidentified	345.0777	51	20	Unidentified
F8	Flurbiprofen	225.0712	139	30	Anti- inflammatory drug

F9	Quaternium-52	610.4093	195	20	Quaternary
					ammonium salt
F10	Ethyl cyanoacrylate	124.0404	14	10	Cyanoacrylate
					glue component
	2-Chloro-4,5-xylyl N-	228.0427	284	10	Cholinesterase
F11	hydroxy-N-				inhibitor
	methylcarbamate				
F12	Psoralen, Angelicin	167.0135	20	20	Skin nodule
	1 soraten, 7 mgenem				treatment,
F13	Hexazinone	273.1344	32	10	Herbicide
F14	MHP (Methyl hydrogen	179.0350	138	10	Organic
	phthalate)				compound
F15	2-Hydroxyphenyl	166.0508	212	10	Pesticide
	methylcarbamate				
F16	Levodopa	178.0510	23	20	Dopamine
	20.0000				precursor drug
F17	Phenylmercuric acetate	337.0157	22	20	Preservative

Table 4. T3DB-annotated m/z features higher in T3 serum of women who subsequently developed breast cancer (BC) compared with those in the non-case women ($P \le 0.05$). Targeted mass spectrometry analysis was performed to aid in identification of features F18-F21 which were found to occur in central communities of Fig 4, indicated by asterisk (*). T3DB annotation is provided for others (F22-F24).

Feature	Name	m/z	RT (sec)	% Higher in BC	Category
F18*	Ergosterol	271.1195	25	10	Vitamin D2 precursor
F19*	Benzoate derivative	214.9728	22.8	10	Food preservative
F20*	Benzo[a]carbazole	217.0866	21	10	Heterocyclic amine
F21*	Glucose	215.0327	23	10	Endogenous metabolite
F22	Trimethadione	142.0509	277	10	Anticonvulsant
F23	Heptabromobiphenyl	734.4246	195	20	Aromatic compound
F24	Chlorpromazine	317.0876	135	10	Antipsychotics

603 **Fig 1.**

Exposome Epidemiology Workflow

Step 1: Archival samples selected for cases and controls



- Step 2: High-resolution mass spectrometry analysis and data extraction
- Step 3: Selection of features positively associated with outcome



Step 4: Annotation of selected features with xenobiotic database



Step 5: Use of annotated features with network analysis tool to identify associated metabolic communities



Step 6: Use of pathway enrichment analysis to gain knowledge concerning the metabolic communities associated with the annotated features



Step 7: Targeted mass spectrometry of selected features to guide future hypothesis-driven research

604 Fig. 2




Fig. 3




Fig. 4




Fig. 5

